These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1158034)

  • 1. Inhibition of labile aggregation-stimulating substance (LASS) and platelet aggregation in diabetes mellitus.
    Colwell JA; Chambers A; Laimins M
    Diabetes; 1975 Jul; 24(7):684-7. PubMed ID: 1158034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylenic analog of arachidonate that acts like aspirin on platelets.
    Willis AL; Kuhn DC; Weiss HJ
    Science; 1974 Jan; 183(4122):327-30. PubMed ID: 4809077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion.
    Weiss HJ; Willis AL; Kuhn D; Brand H
    Br J Haematol; 1976 Feb; 32(2):257-72. PubMed ID: 1247498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered platelet function in diabetes mellitus.
    Colwell JA; Halushka PV; Sarji K; Levine J; Sagel J; Nair RM
    Diabetes; 1976; 25(2 SUPPL):826-31. PubMed ID: 823064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus.
    Halushka PV; Lurie D; Colwell JA
    N Engl J Med; 1977 Dec; 297(24):1306-10. PubMed ID: 917087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihomo-gamma-linolenate suppresses platelet aggregation when administered in vitro or in vivo.
    Willis AL; Comai K; Kuhn DC; Paulsrud J
    Prostaglandins; 1974 Dec; 8(6):509-19. PubMed ID: 4462154
    [No Abstract]   [Full Text] [Related]  

  • 7. An endoperoxide aggregator (Lass), formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance.
    Willis AL; Vane FM; Kuhn DC; Scott CG; Petrin M
    Prostaglandins; 1974 Dec; 8(6):453-507. PubMed ID: 4471695
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel effects of epoxyeicosatrienoic acid isomers: inhibition of platelet aggregation and cyclooxygenase activity.
    Fitzpatrick FA; Ennis MD; Baze ME
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():109-14. PubMed ID: 2959037
    [No Abstract]   [Full Text] [Related]  

  • 9. Labile aggregation stimulating substance, free fatty acids, and platelet aggregation.
    Gerrard JM; White JG; Krivit W
    J Lab Clin Med; 1976 Jan; 87(1):73-82. PubMed ID: 1245785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased platelet aggregation in early diabetus mellitus.
    Sagel J; Colwell JA; Crook L; Laimins M
    Ann Intern Med; 1975 Jun; 82(6):733-8. PubMed ID: 1138583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the mechanism by which eicosapentaenoic acid inhibits human platelet aggregation and secretion - implications for the prevention of vascular disease.
    Jakubowski JA; Ardlie NG
    Thromb Res; 1979; 16(1-2):205-17. PubMed ID: 388720
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased platelet arachidonic acid metabolism in diabetes mellitus.
    Halushka PV; Mayfield R; Wohltmann HJ; Rogers RC; Goldberg AK; McCoy SA; Loadholt CB; Colwell JA
    Diabetes; 1981; 30(Suppl 2):44-8. PubMed ID: 6795072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Butyltin compounds in vitro inhibition of human platelet epinephrine-induced aggregation and blockade of epinephrine binding to platelets.
    Yanagisawa H; Wada O
    Ind Health; 1985; 23(4):255-68. PubMed ID: 3938784
    [No Abstract]   [Full Text] [Related]  

  • 14. [Platelet aggregation induced by adenosine diphosphate, collagen and adrenaline in human platelet subpopulations].
    Nubile G; Di Gregorio M; Ridolfi D; D'Alonzo L; Izzi L
    Quad Sclavo Diagn; 1987 Sep; 23(3):331-40. PubMed ID: 3140287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfonylureas and platelet function.
    Klaff LJ; Kernoff L; Vinik AI; Jackson WP; Jacobs P
    Am J Med; 1981 Mar; 70(3):627-30. PubMed ID: 6782875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombocytopathia with cyclo-oxygenase deficiency].
    Dechavanne M; Lagarde M; Bryon PA
    Nouv Rev Fr Hematol (1978); 1976; 16(3):421-6. PubMed ID: 827736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malondialdehyde formation as an indicator of prostaglandin production by human platelets.
    Smith JB; Ingerman CM; Silver MJ
    J Lab Clin Med; 1976 Jul; 88(1):167-72. PubMed ID: 932533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biphasic effects of phospholipase A2 on platelet aggregation. Effect of prostaglandin synthesis inhibitors and essential fatty acid deficiency.
    Vincent JE; Zijlstra FJ
    Prostaglandins; 1976 Dec; 12(6):971-9. PubMed ID: 1005744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet adhesion and aggregation in diabetes mellitus.
    Colwell JA; Nair RM; Halushka PV; Rogers C; Whetsell A; Sagel J
    Metabolism; 1979 Apr; 28(4 Suppl 1):394-400. PubMed ID: 122293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.